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Continuous human exploitation of environmental resources and an increase in 
human outdoor activities have led to more contact with arthropod vectors, 
promoting an emergence and resurgence of tick-borne pathogens. Clinical trials 
of cetuximab, a monoclonal antibody that inhibits epidermal growth factor 
receptor used for treatment of metastatic colorectal cancer, have shown that the 
drug produces more hypersensitivity than expected, with some fatal cases. 
Patients who developed these hypersensitivity reactions were deemed to have 
pre-existing IgE antibodies specific to the alpha-gal present in the variable 
portion of cetuximab. Further studies have shown that the frequency of anti-
alpha-gal IgE in healthy adults from the US states Tennessee, Virginia, and 
North Carolina was higher than in individuals from Boston or California, or 
northern Sweden. This enigmatic increase in serum anti-alpha-gal IgE 
concentrations in some areas of the USA was due to the lone star tick, 
Amblyomma americanum. The presence of anti-alpha-gal IgE was strongly 
associated with maximum incidence of Rocky Mountain spotted fever (a lethal 
rickettsial illness caused by the A americanum transmitted bacterium Rickettsia 
rickettsii); distribution of A americanum; history of itching after tick bites; and an 
increase in IgE to tick protein concentrations after tick bites, supporting the 
implication of anti-tick immunity in the rise of IgE concentrations. Similar cases 
in Australia, France, Germany, Japan, Spain, and Sweden were associated with 
A americanum, Ixodes ricinus, and Ixodes holocyclus ticks. Clinical outcomes 
are immediateonset anaphylaxis during first exposure to intravenous cetuximab 
and delayed-onset anaphylaxis 3–6h after ingestion of mammalian food 
products (eg, beef and pork). One question arises from these findings: are 
human beings resistant or susceptible tick hosts? Ticks and other 
haematophagous arthropod vectors manipulate the host immune system to 
complete blood feeding, which, in turn, favours pathogen transmission. 
However, the balance between tick manipulation of host immunity and eff ective 
host response, and the implications of these responses on the onset of allergies 
in the host, have not been well established. For instance, the increase in IgE 
concentrations after successive tick infestations has been shown in susceptible 
hosts and associated with resistance to Haemaphysalis longicornis tick 
infestations in mice. Furthermore, results have suggested that the anti-tick IgE 
response, together with recruitment of basophils and mast cells to the tickbite 
site, play a relevant part in host resistance to tick infestation and pathogen 
infection. Simultaneously, tick toxins induce allergic sensitisation that triggers 
development of specific IgE that can bind to receptors present on tissue mast 
cells and blood basophils, causing the release of mediators of allergy and 
anaphylaxis. Protection against tick infestations therefore has the potential to 
induce an allergic reaction in human beings. The effect of ticks and other 
arthropod vectors on host immune response is mediated by proteins in their 
saliva that impair host haemostatic and immune defences. Protein families and 
biological functions of tick saliva are similar to those of other well known 
venomous organisms. Tick saliva has been suggested to be a specialised 
subtype of venom. Venom components are well known antigens that induce 
allergic reactions and have, like tick saliva, a strong intrinsic ability to induce a 
T-helper-2 (Th2)-type immune response.  
Two independent groups have reported that immunisation with bee and snake 
venom produces IgE responses that increase host resistance to challenge with 
potentially lethal doses of venom through IgE receptors and associated mast 
cells. In summary, people who are able to develop an IgE immune response 
and recruit basophils or mast cells to the tick-bite site can show higher 
resistance to tick infestations and tick-borne diseases, but might face major 
risks of anaphylactic reactions to cetuximab and red meat. The implications of 
the strong Th2-type response induced by ticks in the development of host 
allergic reactions should be assessed to understand the balance between tick 
resistance and susceptibility and allergic clinical output. The carbohydrate 
alpha-gal seems to be a good model antigen. The use of tick salivary antigens 
to induce antivenom-like IgE Th2-type protective immune responses should be 
explored to develop anti-tick vaccines. 
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